FULC - CIK 0001680581
The table below shows Fulcrum Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $197.53M | $58.21M | $25.56M | $35.10M | $35.41M | $57.05M |
| Short-term investments | - | - | - | - | - | $0.00 |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $357.48M |
| $249.92M |
| $242.20M |
| $207.52M |
| $226.00M |
| $119.51M |
| Property, plant & equipment | $2.82M | $3.90M | $5.22M | $6.91M | $7.37M | $8.40M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $366.28M | $260.72M | $257.69M | $226.69M | $235.00M | $129.58M |
| Accounts payable | $1.59M | $1.16M | $2.76M | $3.64M | $4.79M | $4.08M |
| Total current liabilities | $13.05M | $11.04M | $13.68M | $16.73M | $19.20M | $26.73M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $17.28M | $17.68M | $22.50M | $27.74M | $23.46M | $34.40M |
| Retained earnings | -$594.28M | -$519.40M | -$509.67M | -$412.34M | -$302.47M | -$221.62M |
| Total equity | $349.00M | $243.03M | $235.19M | $198.94M | $211.54M | $95.18M |